These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11064678)

  • 1. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Crook MA; Lynas J; Wray R
    J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Olukoga AO
    J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
    Crook M; Lynas J; Wray R
    J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
    [No Abstract]   [Full Text] [Related]  

  • 5. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
    Murphy MJ; Duncan A; Vallance BD; Packard CJ; O'Reilly DS
    Postgrad Med J; 1995 Aug; 71(838):498-500. PubMed ID: 7567762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
    Oleesky DA; Mir MA
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M; Sailer S; Irsigler H; Klein W; Patsch JR
    Wien Med Wochenschr; 1995; 145(21):577-83. PubMed ID: 8560901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
    Smith DH; Neutel JM; Jankelow D; Myburgh DP
    S Afr Med J; 1990 May; 77(10):500-3. PubMed ID: 2188379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 15. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
    Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
    Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iatrogenic severe depression of high-density lipoprotein cholesterol.
    Mymin D; Dembinski T; Friesen MH
    J Clin Pharmacol; 2009 Jul; 49(7):865-71. PubMed ID: 19403838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.